Ligand Pharmaceuticals (LGND) Capital Expenditures (2010 - 2026)

Ligand Pharmaceuticals has disclosed Capital Expenditures across 17 years of filings, most recently posting $228000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $228000.0, up 6.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $229000.0 (down 19.08% YoY), and the FY2025 annual result was $215000.0, up 202.82% from the prior year.
• Capital Expenditures came in at $228000.0 for Q1 2026 at Ligand Pharmaceuticals, up from $215000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $75.0 million in Q2 2024 to a low of -$74.7 million in Q3 2024.
• The 5-year median for Capital Expenditures is $214000.0 (2025), against an average of $167470.6.
• Peak annual rise in Capital Expenditures reached 19032.14% in 2024, while the deepest fall reached 3004.78% in 2024.
• Ligand Pharmaceuticals' Capital Expenditures stood at -$1.3 million in 2022, then tumbled by 140.06% to -$3.1 million in 2023, then jumped by 92.98% to -$218000.0 in 2024, then soared by 198.62% to $215000.0 in 2025, then climbed by 6.05% to $228000.0 in 2026.
• The last three Capital Expenditures figures came in at $228000.0 (Q1 2026), $215000.0 (Q4 2025), and -$428000.0 (Q3 2025), per Business Quant data.